Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00810017
Recruitment Status : Terminated (Terminated due to difficulty in accruing patients)
First Posted : December 17, 2008
Last Update Posted : November 7, 2011
Genentech, Inc.
Information provided by (Responsible Party):
Washington Hospital Center

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : May 2010
  Actual Study Completion Date : June 2010